• Sabina Yasmin
  • Venkatesan Jayaprakash Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi-835 215, Jharkhand, India


Nil, Pharmacokinetic parameters, Schrodinger, Structure-activity relationship


Objectives: Thiazolidinediones a promising and privileged scaffold in medicinal chemistry that has been popularly recognized for its antidiabetic activity. The objective of the current study is to explore the effects of substitution replacing the acidic hydrogen of thiazolidinedione ring.

Methods: The protocol adopted was (i) In silico enumeration of small chemical library, (ii) molecular docking simulation and (iii) selection of hits based on predicted ADME/TOX properties to support further synthetic enumeration of chemical compounds for biological evaluation.

Results: The results of the present study showed that all the designed compounds were found to be potent PPARγ modulators and shows promising lead like properties from the calculated ADME/TOX parameters. Rosiglitazone was taken as a standard for the comparison of In silico studies.

Conclusion: The design strategy adopted has predicted improved potency, less toxicity and a better binding mode prediction towards PPARγ.

Keywords: PPARγ, Pharmacokinetic parameters, Schrodinger, Structure-activity relationship, Molecular docking simulation, Pharmacokinetic parameters


Download data is not yet available.


King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.

Pirat Cl, Farce A, Lebègue N, Renault N, Furman C, Millet Rg, et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J Med Chem 2012;55:4027-61.

Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARγ): is the genomic activity the only answer? Steroids 2010;75:585-94.

Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006;58:685-704.

Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996;12:335-63.

Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404.

Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-59.

Han S, Roman J. Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics. Anti-Cancer Drugs 2007;18:237-44.

Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity. Am J Cardiovasc Drugs 2004;4:227-46.

Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nature Med 2001;7:41-7.

Stumvoll M, Häring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217-24.

Martens FMC, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.

Chadha N, Bahia MS, Kaur M, Silakari O. Thiazolidine-2, 4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions. Bioorg Med Chem 2015;23:2953-74.

Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.

Teff T, Reed JE. The antidiabetic PPARγ ligands: an update on compounds in development. Curr Med Chem Immunol Endocrine Metab Agents 2002;2:33-47.

Zhou L, Zhong Y, Xue MZ, Kuang D, Cao XW, Zhao ZJ, et al. Design, synthesis and evaluation of PPAR gamma binding activity of 2-thioxo-4-thiazolidinone derivatives. Chin Chem Lett 2015;26:63-8.

Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclo-hexylmethoxy) benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983;32:804-10.

Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. Br Med J 2012;344:3645–51.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.

Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single-and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther 2011;33:1819-30.

Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066-72.

Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998;395:137-43.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2012;64:4-17.

Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Delivery Rev 2002;54:355-66.

Egan WJ, Zlokarnik G, Grootenhuis PD. In silico prediction of drug safety: despite progress there is abundant room for improvement. Drug Discovery Today Technol 2004;1:381-7.



How to Cite

Yasmin, S., and V. Jayaprakash. “DESIGN, IN-SILICO DOCKING AND PREDICTIVE ADME PROPERTIES OF SOME THIAZOLIDINE-2, 4-DIONES DERIVATIVES AS PPARγ MODULATORS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 5, May 2016, pp. 143-50,



Original Article(s)